REGENXBIO Inc. (RGNX) Dividend History

Company News

• Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases

  Coave Therapeutics, a company pioneering genetic medicines, has established a new Scientific Advisory Board (SAB) with renowned experts in AAV vector biology, gene therapy for ophthalmology and CNS diseases, and extra-hepatic gene delivery. The SAB will provide strategic guidance to support Coave's R&D initiatives and the development of its ALIGATER platform.

  GlobeNewswire Inc.

  Featured Companies: MGTX
• 2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies

  The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.

  GlobeNewswire Inc.

  Featured Companies: ADVM BIIB FDMT JNJ MGTX PASG RARE RCKT SRPT TNYA
• Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

  The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.

  GlobeNewswire Inc.

  Featured Companies: ABEO BCLI CAPR EDIT FDMT FOLD OCGN PFE RARE SGMO
• Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight

  The mucopolysaccharidosis market is witnessing a surge in innovation, driven by cutting-edge gene therapies, enzyme replacement treatments, and novel drug developments. The market is poised for exponential growth with rising awareness, early diagnosis, and increasing investments in rare disease research.

  GlobeNewswire Inc.

  Featured Companies: BMRN DNLI RARE
• Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI

  The global mucopolysaccharidosis treatment market is expected to grow significantly, driven by advancements in biotechnology, improved diagnostic techniques, and increased awareness of rare diseases. The market is projected to reach $5,014.5 million by 2035, growing at a CAGR of 5.9%.

  GlobeNewswire Inc.

  Featured Companies: ABEO BMRN RARE SGMO SRPT